| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
m-PEG8-NHS ester targets primary amine groups (-NH₂) on proteins, peptides, and other biomolecules. The NHS ester reacts with amines to form stable amide bonds. In ADCs, it connects the antibody to the cytotoxic payload. The non-cleavable nature ensures stable payload attachment.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
As a chemical linker, m-PEG8-NHS ester has no intrinsic pharmacological activity. Its utility is defined by its amine-reactive NHS ester group. The PEG8 spacer provides excellent water solubility and flexibility. The monodisperse PEG structure allows precise control over conjugation. |
| ln Vivo |
No direct in vivo activity is attributed to m-PEG8-NHS ester. It functions as a linker in ADCs. The NHS ester group reacts with amines on antibodies to form stable amide linkages. The PEG8 spacer improves solubility and reduces immunogenicity of the final conjugate.
|
| Enzyme Assay |
For non-cell-based assays, m-PEG8-NHS ester is characterized by NMR and HPLC. The NHS ester reactivity can be assessed by reacting with a model amine and monitoring by HPLC or LC-MS. Purity is confirmed by elemental analysis (nitrogen content 2.50-3.00%).
|
| Cell Assay |
Cell-based assays are not performed on m-PEG8-NHS ester alone. It is used to synthesize ADCs, which are then evaluated in cell culture. Standard protocols involve treating cancer cell lines with the ADC at 0.001-10 µM for 24-72 hours. Cytotoxicity is measured by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo studies with m-PEG8-NHS ester are conducted using the final ADC construct. Typical protocols involve administering the ADC to tumor-bearing mouse models via intravenous injection at 1-10 mg/kg. The PEG8 spacer contributes to prolonged circulation and enhanced efficacy.
|
| ADME/Pharmacokinetics |
As a linker, m-PEG8-NHS ester does not have independent PK properties. The PEG8 spacer improves aqueous solubility and reduces clearance. The compound has a molecular weight of 509.55. Storage frozen below 0°C under inert gas is recommended (moisture sensitive).
|
| Toxicity/Toxicokinetics |
Toxicology data specific to m-PEG8-NHS ester are limited. The NHS ester is reactive and may hydrolyze; standard safety precautions apply. The PEG8 moiety is biocompatible.
|
| References | |
| Additional Infomation |
m-PEG8-NHS ester is a non-cleavable 8-unit PEG ADC linker. It is used in the synthesis of antibody-drug conjugates (ADCs). The NHS ester labels primary amines of proteins. No clinical trials exist.
|
| Molecular Formula |
C22H39NO12
|
|---|---|
| Molecular Weight |
509.5446
|
| Exact Mass |
509.247
|
| CAS # |
756525-90-3
|
| PubChem CID |
51340981
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
35
|
| Complexity |
547
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H])=O)N1C(C([H])([H])C([H])([H])C1=O)=O
|
| InChi Key |
IBZNTYBFTKFSMU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H39NO12/c1-27-6-7-29-10-11-31-14-15-33-18-19-34-17-16-32-13-12-30-9-8-28-5-4-22(26)35-23-20(24)2-3-21(23)25/h2-19H2,1H3
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~196.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (9.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (9.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9626 mL | 9.8128 mL | 19.6255 mL | |
| 5 mM | 0.3925 mL | 1.9626 mL | 3.9251 mL | |
| 10 mM | 0.1963 mL | 0.9813 mL | 1.9626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
